Menu Search
Equities

Immunoprecise Antibodies Ltd

TQB:DUS

Immunoprecise Antibodies Ltd

Actions
  • Price (EUR)0.424
  • Today's Change-0.014 / -3.20%
  • Shares traded3.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 18:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.

  • Revenue in USD (TTM)17.21m
  • Net income in USD-19.72m
  • Incorporated2016
  • Employees102.00
  • Location
    Immunoprecise Antibodies Ltd3204-4464 Markham St.VICTORIA V8Z 7X8CanadaCAN
  • Phone+1 (604) 806-0626
  • Fax+1 (250) 483-0309
  • Websitehttps://www.ipatherapeutics.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		IPA:NMQ since
announced		Transaction
value
Carterra Inc-LSA PlatformDeal completed20 Mar 202420 Mar 2024Deal completed-68.28%--
Data delayed at least 15 minutes, as of Nov 14 2024 20:08 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.